• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Lu 标记的生长抑素 2 受体靶向金属组装体的合成:超分子放射疗法设计中的挑战。

Synthesis of Lu-Labeled, Somatostatin-2 Receptor-Targeted Metalla-Assemblies: Challenges in the Design of Supramolecular Radiotherapeutics.

机构信息

Chair of Pharmaceutical Radiochemistry, Department of Chemistry, School of Natural Sciences, Technical University of Munich, Walther-Meißner-Str. 3, 85748 Garching b. München, Germany.

Chair of Medicinal and Bioinorganic Chemistry, Department of Chemistry, School of Natural Sciences, Technical University of Munich, Lichtenbergstr. 4, 85748 Garching b. München, Germany.

出版信息

Inorg Chem. 2023 Dec 18;62(50):20710-20720. doi: 10.1021/acs.inorgchem.3c02090. Epub 2023 Aug 9.

DOI:10.1021/acs.inorgchem.3c02090
PMID:37556427
Abstract

Self-assembled supramolecular coordination complexes (SCCs) hold promise for biomedical applications in cancer therapy, although their potential in the field of nuclear medicine is still substantially unexplored. Therefore, in this study an -functionalized cationic [PdL] metallacycle (L = 3,5-bis(3-ethynylpyridine)phenyl), targeted to the somatostatin-2 receptor (sst2R) and featuring the DOTA chelator (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) in order to bind the β- and γ-emitter lutetium-177, was synthesized by self-assembly following ligand synthesis via standard solid-phase peptide synthesis (SPPS). This metallacycle was then characterized by reverse-phase high-performance liquid chromatography (RP-HPLC), electrospray ionization mass spectrometry (ESI-MS), and H and H-DOSY NMR (DOSY = diffusion-ordered spectroscopy). A procedure for the radiolabeling of the metallacycle with Lu was also optimized. The resulting [Lu]Lu-DOTA-metallacycle, termed [Lu]Lu-, was evaluated concerning its stability and properties. The compound was more lipophilic compared to the reference [Lu]Lu-DOTA-TATE (log = -0.85 ± 0.10 versus -3.67 ± 0.04, respectively). While [Lu]Lu- revealed low stability in a DMEM/F12 GlutaMax medium, it demonstrated good stability in other aqueous media as well as in DMSO. A high sst2R binding affinity (expressed as IC) was determined in CHO cells (Chinese hamster ovary cells that were stably transfected with human sst2R). Moreover, the metallacycle exhibited high human serum albumin binding, as assessed by high-performance affinity chromatography (HPAC), and moderate stability in human serum compared to [Lu]Lu-DOTA-TATE (TATE = (Tyr)-octreotate). In order to improve stability, a heteroleptic approach was used to develop a less sterically hindered cage-like SCC that is potentially endowed with host-guest chemistry capability, which has been preliminarily characterized by RP-HPLC and ESI-MS. Overall, our initial results encourage future studies on sst2R-directed SCCs and have led to new insights into the chemistry of ss2R-directed SCCs for radiopharmaceutical applications.

摘要

自组装超分子配位化合物(SCCs)在癌症治疗的生物医学应用中具有广阔的前景,尽管它们在核医学领域的潜力仍未得到充分探索。因此,在这项研究中,一种 - 功能化的阳离子[PdL]金属环(L = 3,5-双(3-乙炔基吡啶)苯基),靶向生长抑素-2 受体(sst2R),并具有 DOTA 螯合剂(1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸),以便结合β-和γ发射器镥-177,通过配体合成后通过标准固相肽合成(SPPS)自组装合成。然后通过反相高效液相色谱(RP-HPLC)、电喷雾电离质谱(ESI-MS)和 H 和 H-DOSY NMR(DOSY = 扩散有序光谱)对金属环进行了表征。还优化了金属环与 Lu 的放射性标记过程。所得[Lu]Lu-DOTA-金属环,称为[Lu]Lu-,在其稳定性和特性方面进行了评估。与参考[Lu]Lu-DOTA-TATE(log = -0.85 ± 0.10 对-3.67 ± 0.04)相比,该化合物的亲脂性更高。虽然[Lu]Lu-在 DMEM/F12 GlutaMax 培养基中稳定性较低,但它在其他水性介质以及 DMSO 中表现出良好的稳定性。在 CHO 细胞(稳定转染人 sst2R 的中国仓鼠卵巢细胞)中确定了高 sst2R 结合亲和力(表示为 IC)。此外,通过高效亲和色谱(HPAC)评估,金属环与人血清白蛋白的结合率较高,与[Lu]Lu-DOTA-TATE(TATE =(Tyr)-奥曲肽)相比,其在人血清中的稳定性适中。为了提高稳定性,采用杂配位方法开发了一种空间位阻较小的笼状 SCC,该 SCC 可能具有主体-客体化学能力,其初步通过 RP-HPLC 和 ESI-MS 进行了表征。总的来说,我们的初步结果鼓励对 sst2R 导向 SCCs 进行进一步研究,并对 sst2R 导向 SCCs 的化学性质进行了深入了解,为放射性药物应用提供了新的思路。

相似文献

1
Synthesis of Lu-Labeled, Somatostatin-2 Receptor-Targeted Metalla-Assemblies: Challenges in the Design of Supramolecular Radiotherapeutics.Lu 标记的生长抑素 2 受体靶向金属组装体的合成:超分子放射疗法设计中的挑战。
Inorg Chem. 2023 Dec 18;62(50):20710-20720. doi: 10.1021/acs.inorgchem.3c02090. Epub 2023 Aug 9.
2
Bulk Scale Formulation of Therapeutic Doses of Clinical Grade Ready-to-Use Lu-DOTA-TATE: The Intricate Radiochemistry Aspects.大体积配方制备临床级即用型 Lu-DOTA-TATE 治疗剂量:复杂的放射化学方面。
Cancer Biother Radiopharm. 2017 Sep;32(7):266-273.
3
3p-C-NETA: A versatile and effective chelator for development of AlF-labeled and therapeutic radiopharmaceuticals.3p-C-NETA:一种多功能、有效的螯合剂,可用于开发 AlF 标记的治疗放射性药物。
Theranostics. 2022 Aug 8;12(13):5971-5985. doi: 10.7150/thno.75336. eCollection 2022.
4
Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors.长效放射性标记生长抑素类似物 Lu-DOTA-EB-TATE 在晚期转移性神经内分泌肿瘤患者中的安全性、药代动力学和剂量学。
J Nucl Med. 2018 Nov;59(11):1699-1705. doi: 10.2967/jnumed.118.209841. Epub 2018 Apr 13.
5
Preparation of patient doses of (177)Lu-DOTA-TATE using indigenously produced (177)Lu: the Indian experience.使用国产 (177)Lu 制备 (177)Lu-DOTA-TATE 患者剂量:印度经验。
Cancer Biother Radiopharm. 2011 Jun;26(3):395-400. doi: 10.1089/cbr.2010.0881.
6
Design, preparation and biological evaluation of a Lu-labeled somatostatin receptor antagonist for targeted therapy of neuroendocrine tumors.Lu 标记生长抑素受体拮抗剂的设计、制备与靶向治疗神经内分泌肿瘤的生物学评价。
Bioorg Chem. 2020 Jan;94:103381. doi: 10.1016/j.bioorg.2019.103381. Epub 2019 Oct 22.
7
Synthesis, Radiolabeling, and Characterization of Plasma Protein-Binding Ligands: Potential Tools for Modulation of the Pharmacokinetic Properties of (Radio)Pharmaceuticals.血浆蛋白结合配体的合成、放射性标记及表征:调节(放射性)药物药代动力学性质的潜在工具
Bioconjug Chem. 2017 Sep 20;28(9):2372-2383. doi: 10.1021/acs.bioconjchem.7b00378. Epub 2017 Sep 12.
8
In vivo and in vitro evaluation of Lu-labeled DOTA-2-deoxy-D-glucose in mice. A novel radiopharmaceutical agent for cells imaging and therapy.镥标记的DOTA-2-脱氧-D-葡萄糖在小鼠体内和体外的评估。一种用于细胞成像和治疗的新型放射性药物制剂。
Hell J Nucl Med. 2019 May-Aug;22(2):103-110. doi: 10.1967/s002449911002. Epub 2019 Jul 7.
9
Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation.用90Y和177Lu标记的DOTA衍生铃蟾肽类似物的比较研究:体内外评价
Nucl Med Biol. 2009 Aug;36(6):591-603. doi: 10.1016/j.nucmedbio.2009.03.006.
10
Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.).镥[177Lu]标记生长抑素类似物(Lu-177-DOTA-TATE)注射液在放射性核素治疗中的正确使用手册(第 2 版)。
Ann Nucl Med. 2018 Apr;32(3):217-235. doi: 10.1007/s12149-018-1230-7. Epub 2018 Jan 15.

引用本文的文献

1
Editorial: Supramolecular cancer therapeutic biomaterials-volume II.社论:超分子癌症治疗生物材料——第二卷
Front Chem. 2025 Mar 5;13:1574334. doi: 10.3389/fchem.2025.1574334. eCollection 2025.
2
Assembling a new generation of radiopharmaceuticals with supramolecular theranostics.用超分子诊疗学组装新一代放射性药物。
Nat Rev Chem. 2024 Dec;8(12):893-914. doi: 10.1038/s41570-024-00657-4. Epub 2024 Oct 28.
3
Metals in Cancer Research: Beyond Platinum Metallodrugs.癌症研究中的金属:超越铂类金属药物
ACS Cent Sci. 2024 Feb 7;10(2):242-250. doi: 10.1021/acscentsci.3c01340. eCollection 2024 Feb 28.